SemenBoost

Evidence

Supplements and male fertility

How SemenBoost reads supplement evidence: semen-parameter changes are not pregnancy results, and no affiliate deal decides the conclusion.

Published
Modified
Clinician review
Not yet

Short answer

Some oral supplements have been studied in men with abnormal semen analyses. A reported improvement in count, motility or morphology is not evidence of more pregnancies or live births. The 2022 Cochrane review of antioxidants found only very low-certainty evidence on live birth, and that signal was lost when high-risk-of-bias trials were removed. SemenBoost has no approved affiliate relationship for any ingredient.

Key takeaways

  • Parameter evidence and outcome evidence are shown separately.
  • Studied doses are descriptions of trials, not recommendations.
  • Commercial products are not mixed into the evidence section.
  • Supplements do not replace a semen analysis or treatment of a cause such as steroids or a blockage.

Ingredients

How to read an evidence rating

Strong, moderate, limited and insufficient are assigned by hand on each page, with a written reason. They are not generated from a keyword. If a page cannot separate semen findings from baby-born findings, it is not ready to publish a rating.

Evidence

Limited evidence

Across antioxidants as a class, evidence that supplements improve live birth is very low certainty. Evidence about individual semen parameters depends on the ingredient and is not automatically even limited.

Semen parameters

Limited evidence

Trials of several ingredients report changes in concentration, motility or morphology. Quality and consistency vary.

Pregnancy and live birth

Insufficient evidence

Cochrane 2022: very low-certainty live-birth evidence that was not present after removing trials at high risk of bias. That is not a basis for telling someone a supplement will help them conceive.

A change in a semen measurement is not the same finding as a pregnancy or a live birth.

Related

Sources

  1. Antioxidants for male subfertility — Cochrane, 2022
  2. Fertility problems: assessment and treatment (NG257) — NICE, 2026
How this page was prepared

Drafted with automated research assistance and checked against the cited primary sources. A named clinician has not reviewed this page. Medical review is pending. Changes to reference values are not published automatically.